BioAge Labs, Inc. (BIOA)
NASDAQ: BIOA · Real-Time Price · USD
17.99
+0.17 (0.95%)
May 8, 2026, 4:00 PM EDT - Market closed
BioAge Labs Employees
As of December 31, 2025, BioAge Labs had 62 total employees, including 60 full-time and 2 part-time employees. The number of employees decreased by 2 or -3.13% compared to the previous year.
Employees
62
Change (1Y)
-2
Growth (1Y)
-3.13%
Revenue / Employee
$166,387
Profits / Employee
-$1,450,484
Market Cap
798.72M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 62 | -2 | -3.13% | 60 | 2 |
| Dec 31, 2024 | 64 | 8 | 14.29% | 62 | 2 |
| Jun 30, 2024 | 60 | - | - | 58 | 2 |
| Mar 31, 2024 | 56 | - | - | 54 | 2 |
| Dec 31, 2023 | 56 | - | - | 54 | 2 |
Related Stocks
| Company Name | Employees |
|---|---|
| Evotec SE | 4,467 |
| Tilray Brands | 2,842 |
| Amphastar Pharmaceuticals | 1,976 |
| Alvotech | 1,279 |
| Pacira BioSciences | 829 |
| Cronos Group | 610 |
| Xeris Biopharma Holdings | 435 |
| Esperion Therapeutics | 294 |
BIOA News
- 1 day ago - BioAge Labs Transcript: Status update - Transcripts
- 1 day ago - BioAge Labs reports Q1 EPS (52c), consensus (63c) - TheFly
- 1 day ago - BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 days ago - BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026 - GlobeNewsWire
- 18 days ago - BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2 - TheFly
- 18 days ago - BioAge Labs Transcript: Study result - Transcripts
- 18 days ago - BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP - GlobeNewsWire
- 23 days ago - BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts